Antimicrobial resistance in Acinetobacter baumannii poses a significant global health challenge. Phage therapy, particularly through phage-antibiotic synergy (PAS), offers a promising strategy to combat this pathogen. This study demonstrated significant PAS, where the combination of phage Indie and ceftazidime achieved a bacterial reduction of more than 85% of A. baumannii strain AbAK03 at 17 h using low doses. Notably, this combination overcame phage resistance observed at 4 h when the phage was used alone, extending bacterial eradication by 13 h. Furthermore, phage Indie restored bacterial susceptibility to ceftazidime, supporting its role in improving interventional treatments against multidrug-resistant A. baumannii. To explore this interaction, phage Indie was isolated and characterized from multidrug-resistant clinical strains. An in vitro PAS experiment was performed using ceftazidime and piperacillin-tazobactam. The combination of phage Indie with ceftazidime consistently showed superior bactericidal effects compared to either agent alone, while the combination of phage Indie with piperacillin-tazobactam exhibited an antagonistic effect. These findings provide clear evidence supporting the application of phage-antibiotic combinations as an effective intervention strategy and lay the groundwork for future in vivo trials in a mouse model to combat antimicrobial resistance.
• Phages M3, C2, M9, and M83 belong to a new species of the genus of Maculvirus and phages ALK and CHI belong to new genus of the Queuovirinae subfamily. • CHI, ALK, M3, C2, M9, and M83 could lyse 50.0% (5/10) of Mexican AHPND-causing Vibrio parahaemolyticus strains. • No transfer RNA (tRNA), virulence, or antibiotic resistance genes were found in phage genomes. • CHI, ALK, M3, C2, M9, and M83 significantly reduced the growth of Mexican AHPND-causing Vibrio parahaemolyticus strains after incubating with MOI of 0.01–1.
Acinetobacter baumannii is an opportunistic pathogen and a major cause of nosocomial infections worldwide. This study aimed to isolate and characterize phages with lytic activity against multidrug-resistant A. baumannii strains to enable antibacterial alternatives. Eight phages (AKO8a, PS118, B612, MCR, IDQ7, 89P13, CRL20, and CIM23) were isolated and subjected to genomic, phylogenetic, and functional analyses. Antibacterial activity was assessed in vitro against A. baumannii strain AbAK04 by measuring optical density over 17 h at multiplicities of infection (MOIs) of 0.1, 1, and 10, using a repeated-measures design with time as a crossed factor and MOI as a nested factor. Tukey’s post-hoc test identified significant bacterial growth reductions of 57–72% (p < 0.001). Specifically, phages PS118 and 89P13 reduced growth by 71% at MOI 10; CIM23, B612, and CRL20 achieved 68% reduction at MOI 1; and MCR reduced growth by 64% at MOIs 0.1 and 1. Notably, lytic phage MCR encodes a glycosyl hydrolase family 58 (GH58) enzyme, potentially contributing to its antibacterial activity. Genomic analyses confirmed absence of virulence and antibiotic resistance genes, with all phages classified as novel species within the Kagunavirus genus. These findings support the use of these phages as promising candidates for in vivo evaluation.